版本:
中国

BRIEF-Mei Pharma says one patient in ME-401 study experienced grade 3 neutropenia

May 31 Mei Pharma Inc:

* Mei Pharma announces pre-specified response rate exceeded in dose-escalation study of ME-401 in chronic lymphocytic leukemia and follicular lymphoma

* Mei Pharma -independent safety review committee finds no dose limiting toxicities, declares minimum biologically effective dose, recommends dose escalation

* Mei Pharma Inc says there have been no reports of ALT/AST elevations, colitis or pneumonitis, events commonly reported with other drugs in the class

* Mei Pharma Inc says one patient in study experienced grade 3 neutropenia that was considered related to study drug Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐